Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status-Reference-Cited by-同舟云学术

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status

Published:2007-10 Issue:5 Volume:9 Page:
ISSN:1465-542X
Container-title:Breast Cancer Research
language:en
Short-container-title:Breast Cancer Res

Author:

Fehm Tanja,Becker Sven,Duerr-Stoerzer Silke,Sotlar Karl,Mueller Volkmar,Wallwiener Diethelm,Lane Nancy,Solomayer Erich,Uhr Jonathan

Publisher

Springer Science and Business Media LLC

Link

http://link.springer.com/content/pdf/10.1186/bcr1783.pdf

Reference42 articles.

1. Coussens L, Yang-Feng TL, Lioa YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985, 230: 1132-1139. 10.1126/science.2999974.

2. Schecter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg AR: The neu oncogene : An erbB-related gene encoding a 185,000-Mr tumor antigen. Nature. 1984, 312: 513-516. 10.1038/312513a0.

3. Slamon DJ, Goldolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al: Studies of the HER-2/proto-oncogene in human breast cancer and ovarian cancer. Science. 1989, 244: 707-712. 10.1126/science.2470152.

4. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, et al: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003, 95: 142-153.

5. Moliterni A, Menard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, Casalini P, Tomasic G, Marubini E, Pilotti S, Bonadonna G: HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol. 2003, 21: 458-462. 10.1200/JCO.2003.04.021.

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screen-Printed Electrodes as Low-Cost Sensors for Breast Cancer Biomarker Detection;Sensors;2024-08-31

2. Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models;British Journal of Cancer;2024-04-10

3. A Ti3C2 modified single electrode electrochemical system for the gold nanoprism-enhanced ECL detection of HER2;Journal of Electroanalytical Chemistry;2024-03

4. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells—The DETECT III Clinical Trial;Clinical Chemistry;2024-01

5. Real-time assessment of HER2 status in circulating tumor cells of breast cancer patients: Methods of detection and clinical implications;The Journal of Liquid Biopsy;2023-12